ArticleParasites & vectors2013
Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis.
Article in Parasites & vectors, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Molecular characterization of a novel Trichinella spiralis aspartyl protease and its role in the larval invasion of host intestinal epithelial cells.Parasite (Paris, France) · 2026Article
- REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.The Journal of parasitology · 2021Review
- Review
- With Chitosan and PLGA as the Delivery Vehicle,Frontiers in immunology · 2021Article
- Calcium-dependent protein kinases are potential targets forClinical and experimental vaccine research · 2018Review
- DNA Vaccines Encoding Toxoplasma gondii Cathepsin C 1 Induce Protection against Toxoplasmosis in Mice.The Korean journal of parasitology · 2017Article
- Protection via a ROM4 DNA vaccine and peptide against Toxoplasma gondii in BALB/c mice.BMC infectious diseases · 2017Article
- Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.BMC infectious diseases · 2017Article
- Sixty Years (1957-2017) of Research on Toxoplasmosis in China-An Overview.Frontiers in microbiology · 2017Review
- The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2016Article
- Epitope analysis and protection by a ROP19 DNA vaccine against Toxoplasma gondii.Parasite (Paris, France) · 2016Article
- Protective immunity against acute toxoplasmosis in BALB/c mice induced by a DNA vaccine encoding Toxoplasma gondii elongation factor 1-alpha.BMC infectious diseases · 2015Article
- New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74.Human vaccines & immunotherapeutics · 2015Article
- Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection.Parasites & vectors · 2014Article
- High expression of water-soluble recombinant antigenic domains of Toxoplasma gondii secretory organelles.The Korean journal of parasitology · 2014Article
- Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii.Parasites & vectors · 2014Review
- Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice.Parasites & vectors · 2014Article
- Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.PloS one · 2013Article
- Immunogenicity of Multiepitope Vaccine Candidate againstIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToxoplasma gondii is an obligate intracellular parasite that can pose a serious threat to human health by causing toxoplasmosis. There are no drugs that target the chronic cyst stage of this infection; therefore, development of an effective vaccine would be an important advance. Aspartic proteases play essential roles in the T. gondii lifecycle. The parasite has four aspartic protease encoding genes, which are called toxomepsin 1, 2, 3 and 5 (TgASP1, 2, 3 and 5, respectively).
methodsBioinformatics approaches have enabled us to identify several promising linear-B cell epitopes and potential Th-cell epitopes on TgASP1, thus supporting its potential as a DNA vaccine against toxoplasmosis. We expressed TgASP1 in Escherichia coli and used the purified protein to immunize BALB/c mice. The antibodies obtained were used to determine where TgASP1 was localized in the parasite. We also made a TgASP1 DNA vaccine construct and evaluated it for the level of protection conferred to mice against infection with the virulent RH strain of T. gondii.
resultsTgASP1 appears to be a membrane protein located primarily at the tip of the T. gondii tachyzoite. Investigation of its potential as a DNA vaccine showed that it elicited strong humoral and cellular immune responses in mice, and that these responses were mediated by Th-1 cells. Mice immunized with the vaccine had greater levels of protection against mortality following challenge with T. gondii RH tachyzoites than did those immunized with PBS or the empty vector control.
conclusionsTgASP1 is a novel candidate DNA vaccine that merits further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.